INTRODUCTION
Gastric cancer is the fourth most common cancer and second leading cause of cancerrelated death worldwide [1] , even though the incidence of gastric cancer has shown a dramatic decrease over the past half-century. The highest prevalence of gastric cancer has been reported in Japan, China, South America, Eastern Europe, and the Middle East. In Iran, gastric cancer is the leading and second major cause of cancerrelated mortality among men and women, respectively. It is a multi-factorial disease, with a wide variety of genetic and environmental factors involved in its etiology, including chronic inflammation, Helicobacter pylori infection, exposure to diverse carcinogens, genetic susceptibility, tobacco smoking, high-salt intake, diets with insu cient antioxidant levels, and lifestyle factors [2, 3] . Gastric carcinoma can be divided into two broad categories based on clinicopathologic factors: i) early gastric cancers (EGCs) limited to mucosa and submucosa, and including the protruded, super cial, and excavated types, and ii) adenocarcinomas, which extend at least into muscularis propria [3] . Epigenetic mechanisms contribute to all the steps of cancer development and progression, and deregulation of DNA methylation, a reversible process, is known to exert profound in uence on cancer. In normal cells, CpG islands in the promoter regions of genes are unmethylated, whereas repetitive elements and transposons are mostly methylated [4] . Aberrant methylation of promoter regions is an epigenetic abnormality of the human genome, which is highly characteristic of cancer.
Cytotoxic T-lymphocyte-associated antigen-4 (CTLA4), encoded by the human CTLA4 gene, is a receptor belonging to the immunoglobulin superfamily, and is expressed on the surface of activated T cells. CD28 and CTLA4 share the ligands CD80 (also known as B7.1) and CD86 (or B7.2), which share identical functions [5, 6] . CTLA4 consists of 149 amino acids, and is expressed exclusively in activated CD4+ and CD8+ J Gastrointestin Liver Dis, September 2014 Vol. 23 No 3: 249-253 T lymphocytes [7] ; it binds to B7 molecules on antigenpresenting cells, and could be considered a two-blade knife, as its optimal expression ensures an e ective, but at the same time, safe immune response [8] .
CTLA4 has much higher overall a nities for both CD80 and CD86 ligands compared to CD28; it has been proposed that CTLA4 expression on the surface of T cells regulates T-cell activation by outcompeting CD28 for ligand binding, as well as by actively delivering inhibitory signals to the T cell [9] . However, CTLA4 also confers 'signaling-independent' T-cell inhibition through sequestration of CD80 and CD86 ligands from CD28 engagement. Furthermore, CTLA4 plays a pivotal role in cancer development and progression [10] . Increased levels of regulatory T cells (T-reg) and CTLA4 have been observed in patients with di erent types of cancer compared to control individuals, and higher CTLA4 expression has been associated with a severe prognosis of cancer; a DNA vaccine against CTLA4 has also been shown to prevent tumor growth [11] [12] [13] . Moreover, antibodies that block the activity of this receptor have been reported to improve survival in patients with dissimilar types of cancer [9] . e human CTLA4 gene is located on the long arm of chromosome 2q33 within 25-150 kb of the gene encoding CD28. ere are at least three polymorphic markers associated with CTLA4, a C to T polymorphism at 318 position of the promoter region, an A/G transition at position 49 of exon 1, resulting in a substitution of r17 to Ala, and an (AT)n dinucleotide repeat polymorphism located in the 3' UTR of exon 4 [14] . e aim of this study was to analyze promoter methylation, polymorphism, and expression level of CTLA4 in patients with gastric cancer.
MATERIAL AND METHODS

Patients and tissue samples
Eighty five samples of paraffin-embedded gastric adenocarcinoma tissues were obtained from the Pathology service of Alzahra Hospital in Isfahan, Iran. e samples were derived from patients who had undergone a curative gastrectomy during the period 2009-2012. Control samples, also 85 in number, were obtained from the una ected normal tissue at the tumor margins; they were con rmed as noncancerous by pathologists.
DNA extraction, modi cation, and methylation-speci c PCR (MSP)
Genomic DNA was extracted from para n-embedded tissues as previously described. Bisul te modi cation for the conversion of unmethylated cytosine to uracil, while leaving methylated cytosine unaltered, was carried out using 2 µg of DNA. Wizard® DNA Clean-Up System (Promega, Madison, WI) was employed for sodium bisul te conversion according to the supplier's protocol. Methylation-speci c PCR (MSP) was performed using primers speci c for the methylated (M) or unmethylated (U) alleles of CTLA4 gene; the primer sequences and annealing temperatures are summarized in Table I . Each PCR reaction contained 1 µL of bisul te-modi ed DNA, 0.5 µL of HS-Taq DNA polymerase (2.5 U/µL, Cat. No. 01011, Pars Tous Biotechnology), 2.5 µL of 10X bu er, 0.8 mM dNTP mix, 0.4 mM of each primer, and 1.5 mM Mg
2+
; the reaction was made up to a nal volume of 25 µL using RNase-free double-distilled water The MSP amplification conditions included initial denaturation step at 95°C for 10 min, 40 cycles of 95°C for 30 s, 63°C (M) or 59°C (U) for 40 s, and 72°C for 40 s, followed by 1 cycle of nal extension at 72°C for 10 min.
e PCR products were analyzed by electrophoresis using 3% agarose gel followed by ethidium bromide staining and visualization using UV transilluminator.
RNA extraction and RT-PCR
Isolation of total RNA from para n-embedded tissues was performed using CinnaPure RNA kit (Cat. No. PR891620, Tehran, Iran) according to the manufacturer's protocol. Subsequently, rst-strand cDNA was synthesized from 1-10 µg of total RNA using 2-steps RT-PCR kit (Cat. No. RTPL12, Vivantis Technologies) according to the supplier's protocol. Real-time PCR was performed in reactions of 16 µl volume containing Power SYBR Green PCR Master Mix (Applied Biosystems); Applied Biosystems Real-Time PCR instrument Table I was employed, and the reaction conditions included initial denaturation at 95°C for 10 min, 40 cycles of 95°C for 15 s, 60°C for 30 s, and 72°C for 40 s, followed by 1 cycle of nal extension at 72°C for 10 min; nally, the melting curve was obtained over the range 60-95 °C. e sequences of the primers used for expression analysis are listed in Table I . e expression of CTLA4 was normalized to 18s rRNA internal control, and analyzed using the 2 -∆∆CT method.
Statistical analysis SPSS Version 20 was used for statistical analyses. Categorical data was analyzed using chi-squared test (χ2), and the association between CTLA4 gene methylation and risk of gastric cancer was examined by estimating odds ratio (OR) and 95% con dence interval (95%CI) using binary logistic regression analysis. Mann-Whitney test was used for comparing expression data between tumor samples and their margins. e level of statistical signi cance was set at p ≤ 0.05.
RESULTS
e demographic, pathological, and clinical characteristics of the participants are presented in Table II .
Methylation of the CTLA4 gene was associated with a greatly increased risk of gastric cancer compared to the unmethylated pattern as a reference (OR = 4.829, 95% CI: 2.46-9.48, p < 0.001) (Table III) . e frequency of methylation of the CTLA4 gene promoter in tumor samples and their margins was 78.82% and 43.53%, respectively. Table IV details the frequency of methylation patterns corresponding to each clinical characteristic of the tumor samples. Signi cant differences were observed between CTLA4 expression in cancerous tissue (n = 25, mean ± SD: 7.56 ± 17.35) and their normal margins (n = 25, mean ± SD: 15.45 ± 7.96, p < 0.001), as shown in Table V. e frequencies of -318 C/T and +49 A/G polymorphisms of CTLA4 gene in gastric cancer patients are shown in Table VI . (20) 5 (25) 52 (80) 15 (75) 0.63 
DISCUSSION
Our results indicate that the methylation of CTLA4 gene is associated with an increased risk of gastric cancer, and signi cantly lower expression of this gene could be observed in cancer tissues relative to their normal margins. Along these lines, Zhou et al (2013) reported that CTLA4 expression in ALL patients was higher just prior to their death than at the time of recruitment [15] . Polymorphisms in CTLA4 are associated with various types of cancer, and increased expression of CTLA4 mRNA or protein has been found in several tumor types; for instance, increased CTLA4 expression was observed in a majority of non-small cell lung cancer (NSCLC) patients [16] . A few studies have demonstrated that blocking of CTLA4 receptor results in antitumor activity, reduced metastatic behavior, and durable tumor regressions in certain patients (Kwon et progression of lung cancer [17] . Moreover, Liu-sheng et al (2012) found that increased intratumoral T-reg lymphocytes are associated with the tumor stage in human gastric cancer [18] . Further, Verma et al (2013) highlighted that the blood of patients with large and locally-advanced breast cancers (LLABCs) shows signi cantly increased circulating CTLA4+ T-reg cells compared to healthy, age-matched female donors (HFDs); signi cantly elevated CTLA4 mRNA levels were also observed in LLABCs compared to HFDs [19] . e expression of CTLA4 is a key factor for the formation of a self-reactive TCR repertoire of natural T-reg cells [20] . High expression levels of PD-L1, PD-L2, PD-1, and CTLA4 have been reported in myelodysplastic syndrome [21] . Certain studies have indicated that genetic polymorphisms in CTLA4 are associated with susceptibility to various types of cancer [22] . On the other hand, individuals with GG genotype at position +49 of CTLA4 have been suggested to be more susceptible to autoimmune disorders, while those with AA genotype, to have a higher likelihood of cancer progression [23] . Two polymorphisms of CTLA4 gene (+49 A/G and -1661 A/G) have been shown to be risk factors for breast and oral cancers [24] . Investigation of the +6230 G/A polymorphism in the Asian population revealed the association of this polymorphism with increased risk of breast and cervical cancers [25] .
Information obtained until now suggests that various factors, including genetic, epigenetic, and environmental factors, could be involved in gastric cancer development. Gastric cancer is among the most common malignancies worldwide, and is o en diagnosed only in advanced stages.
erefore, identi cation of genetic and epigenetic alterations and factors a ecting the incidence of this cancer can help in early detection and treatment of this dangerous disease.
CONCLUSION
While previous studies have shown high levels of CTLA4 mRNA or protein in the blood of patients with multiple types of cancer, the present study indicates that gene silencing and reduction in CTLA4 expression are possibly related to promoter hypermethylation of its gene, and that it can be considered a risk factor for gastric cancer. ese results raise the possibility that CTLA4 could be considered as a potential therapeutic target for gastric cancer. As the current study is the rst one dealing with this subject, there is a limitation with regard to comparing the current data with that of other studies. Further investigation of all the components involved in the CTLA4 pathway, in a study involving larger sample sizes and various populations, is therefore required for a better understanding of the role of CTLA4 gene in the development of gastric cancer and its prognosis.
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